Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.

[1]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.

[2]  K. Rahbar,et al.  Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis , 2016, The Journal of Nuclear Medicine.

[3]  S. Vallabhajosula,et al.  Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. , 2016, Current radiopharmaceuticals.

[4]  R. Baum,et al.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy , 2016, The Journal of Nuclear Medicine.

[5]  R. Lutz,et al.  Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. , 2011, Bioconjugate chemistry.

[6]  H. Rugo,et al.  Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Suzanne F. Jones,et al.  Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Beltran,et al.  Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer , 2010, Cancer.

[9]  H. Scher,et al.  Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Silva,et al.  A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer , 2004, Cancer Research.

[11]  D. Fishman,et al.  Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy , 2003, International Journal of Gynecologic Cancer.

[12]  A. Tolcher,et al.  Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.